Core Insights - Iradimed Corporation reported record revenue of $20.4 million for Q2 2025, marking a 14% increase year-over-year, and a GAAP diluted EPS of $0.45, up 18% year-over-year [3][9][10] - The company raised its full-year 2025 revenue guidance to a range of $80.0 million to $82.5 million, and GAAP diluted EPS guidance to $1.60 to $1.70 [4][17] - A quarterly cash dividend of $0.17 per share was declared, payable on August 28, 2025 [5][9] Financial Performance - For Q2 2025, net income was reported at $5.8 million, an 18% increase from $4.9 million in Q2 2024, translating to $0.45 per diluted share [6][10] - Non-GAAP net income for Q2 2025 was $6.4 million, a 19% increase from $5.4 million in Q2 2024, with non-GAAP diluted EPS at $0.49, up 17% [7][11] - For the first half of 2025, total revenue reached $39.9 million, a 12% increase from $35.5 million in the same period of 2024, with net income of $10.5 million, up 16% [10][11] Operational Highlights - The gross profit margin for Q2 2025 was 78%, consistent with the same period in 2024, driven by increased overhead absorption [3][12] - Domestic sales accounted for 89% of total revenue in Q2 2025, compared to 86% in Q2 2024 [12] - The company completed the construction of a new facility in Orlando, Florida, with total construction costs of approximately $12.6 million [16] Future Outlook - For Q3 2025, the company expects revenue between $20.5 million and $20.9 million, with GAAP diluted EPS guidance of $0.41 to $0.45 [4][17] - The anticipated commercialization of a next-generation MRI-compatible IV infusion pump is expected to drive sustained growth starting late 2025 [3][4]